Evidence map›Paper›PMID 35516124›Full record

ArticleRSC advances2019

Machine learning algorithms enhance the specificity of cancer biomarker detection using SERS-based immunoassays in microfluidic chips.

Nariman Banaei, Javad Moshfegh, Arman Mohseni-Kabir, Jean Marie Houghton, Yubing Sun, Byung Kim

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review: Detection of Cancer Biomarkers from a Clinical Perspective.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Nariman BanaeiDepartment of Mechanical and Industrial Engineering, University of Massachusetts Amherst Amherst MA USA ybsun@umass.edu kim@engin.umass.edu.ORCID https://orcid.org/0000-0002-9230-7514
Javad MoshfeghDepartment of Electrical and Computer Engineering, University of Massachusetts Amherst MA USA.
Arman Mohseni-KabirDepartment of Physics, University of Massachusetts Amherst MA USA.
Jean Marie HoughtonDepartment of Medicine, University of Massachusetts Medical School Worcester MA USA.
Yubing SunDepartment of Mechanical and Industrial Engineering, University of Massachusetts Amherst Amherst MA USA ybsun@umass.edu kim@engin.umass.edu.ORCID https://orcid.org/0000-0002-6831-3383
Byung KimDepartment of Mechanical and Industrial Engineering, University of Massachusetts Amherst Amherst MA USA ybsun@umass.edu kim@engin.umass.edu.
Amherst College · USUniversity of Massachusetts Chan Medical School · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Specificity is a challenge in liquid biopsy and early diagnosis of various diseases. There are only a few biomarkers that have been approved for use in cancer diagnostics; however, these biomarkers suffer from a lack of high specificity. Moreover, determining the exact type of disorder for patients with positive liquid biopsy tests is difficult, especially when the aberrant expression of one single biomarker can be found in various other disorders. In this study, a SERS-based protein biomarker detection platform in a microfluidic chip and two machine learning algorithms (K-nearest neighbor and classification tree) are used to improve the reproducibility and specificity of the SERS-based liquid biopsy assay. Applying machine learning algorithms to the analysis of the expression level data of 5 protein biomarkers (CA19-9, HE4, MUC4, MMP7, and mesothelin) in pancreatic cancer patients, ovarian cancer patients, pancreatitis patients, and healthy individuals improves the chance of recognition for one specific disorder among the aforementioned diseases with overlapping protein biomarker changes. Our results demonstrate a convenient but highly specific approach for cancer diagnostics using serum samples.

Identifiers

PMID35516124
PMCPMC9059745
OpenAlexW2910323350

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.